When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study
CONCLUSION: Ours is the first pan-Canadian IMID assessment of how vaccine history and other factors affect serologic COVID-19 vaccine responses. These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when >6 months has elapsed since last COVID vaccination/infection.PMID:38621797 | DOI:10.3899/jrheum.2023-1214 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Dawn M E Bowdish Vinod Chandran Carol A Hitchon Gilaad G Kaplan J Antonio Avina-Zubieta Paul R Fortin Maggie J Larch é Gilles Boire Anne-Claude Gingras Roya M Dayam Ines Colmegna Luck Lukusa Jennifer L F Lee Dawn P Richards Daniel Pereira Tania H Watts M Source Type: research
Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition
Psoriasis (PSO) and psoriatic arthritis (PsA) are Th17-driven inflammatory diseases where interleukin (IL)-17 cytokines like IL-17A and IL-17F promote disease pathogenesis. There are six IL-17 isoforms (IL-17A –F) and five IL-17 receptors (IL-17RA–E; Liu et al., 2020). IL-17 cytokines primarily function as homodimers, although IL-17A and IL-17F can heterodimerize (Brembilla et al., 2018). IL-17A and IL-17F genes share the same chromosomal location (6p12), their proteins share ∼55% sequence homology, and both cytokines signal through the IL-17RA/RC heterodimeric complex (Brembilla et al., 2018, Liu et al., 2020). (Sou...
Source: Journal of Investigative Dermatology - April 15, 2024 Category: Dermatology Authors: Ralph Adams, Christopher G. Bunick, Alastair D.G. Lawson, Braulio Gomez, Stevan Shaw Tags: Letters to the Editor Source Type: research
Construct validity, reliability, and threshold value for treatment goals of the Thai version of the 12 ‐item Psoriatic Arthritis Impact of Disease Questionnaire for patients with psoriatic arthritis
ConclusionsThe Thai-PsAID is a valid, reliable, and feasible tool for measuring PsA prognosis. A cutoff of 2.7 accurately discriminates MDA and PASS and indicates no need for medication escalation. The Thai-PsAID may be used as a standalone measure. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - April 13, 2024 Category: Rheumatology Authors: Praveena Chiowchanwisawakit,
Annop Orawongpaisarn,
Wanruchada Katchamart Tags: ORIGINAL ARTICLE Source Type: research
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Rev Clin Pharmacol. 2024 Apr 11:1-17. doi: 10.1080/17512433.2024.2340552. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor nec...
Source: Expert Review of Clinical Pharmacology - April 11, 2024 Category: Drugs & Pharmacology Authors: Laura L Mateu-Arrom Lluis L Puig Source Type: research
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Rev Clin Pharmacol. 2024 Apr 11:1-17. doi: 10.1080/17512433.2024.2340552. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor nec...
Source: Pharmacological Reviews - April 11, 2024 Category: Drugs & Pharmacology Authors: Laura L Mateu-Arrom Lluis L Puig Source Type: research
Ultrasonographic and power doppler parameters of nails fail to differentiate between onychodystrophy in patients with psoriasis vulgaris or psoriatic arthritis
CONCLUSION: Greater nail bed thickness indicates early psoriatic nail disease, as confirmed in our study correlating NAPSI with nail bed thickness. Ultrasonography is a low-cost exam, promising in the evaluation, showing that the ultrasound grayscale is consistent with those who have dystrophic nails, but it can't distinguish psoriasis from psoriatic arthritis, even in those with nail dystrophy.PMID:38605415 | DOI:10.1186/s42358-024-00367-x (Source: Adv Data)
Source: Adv Data - April 11, 2024 Category: Epidemiology Authors: Anber Ancel Tanaka Betina Werner Annelise Correa Bueno Bragatto Thelma Larocca Skare B árbara Stadler Source Type: research
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Rev Clin Pharmacol. 2024 Apr 11:1-17. doi: 10.1080/17512433.2024.2340552. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor nec...
Source: Expert Review of Clinical Pharmacology - April 11, 2024 Category: Drugs & Pharmacology Authors: Laura L Mateu-Arrom Lluis L Puig Source Type: research
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Expert Rev Clin Pharmacol. 2024 Apr 11:1-17. doi: 10.1080/17512433.2024.2340552. Online ahead of print.ABSTRACTINTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor nec...
Source: Pharmacological Reviews - April 11, 2024 Category: Drugs & Pharmacology Authors: Laura L Mateu-Arrom Lluis L Puig Source Type: research
